Use of 5'-monophosphate nucleotide composition in preparing Anti-aging and lifespan-extending medicament and / or functional food
By leveraging the synergistic effect of a specific ratio of 5'-monophosphate nucleotide composition and nutritional supplements, the problem of the single mechanism of existing anti-aging products is solved, achieving multi-pathway synergistic anti-aging, significantly delaying aging and extending lifespan.
Patent Information
- Application Number
- PCT/CN2025/123872
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2025-09-25
- Publication Date
- 2026-11-12
AI Technical Summary
Existing anti-aging products have a single mechanism, limited effects, lack systematic research, and are difficult to comprehensively improve the aging state.
A specific ratio of 5'-monophosphate nucleotides, including 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotides, combined with nutritional supplements such as pyrroquinone, curcumin, resveratrol, and 6-gingerol, works synergistically to scavenge free radicals, improve cell metabolism, and regulate the blood system, nervous system, and gut microbiota, achieving multi-pathway synergistic anti-aging.
It significantly delays aging and prolongs healthy lifespan by improving glucose and lipid metabolism, reducing the risk of diabetes, enhancing blood flow, protecting the stability of the nervous system, regulating the balance of gut microbiota, and increasing mitochondrial activity. It extends the median survival time of mice by 9.21–12.6%, and is estimated to extend human lifespan by 8.76–12.01 years.
Smart Images

Figure CN2025123872_12112026_PF_FP_ABST
Abstract
Description
Application of 5'-monophosphate nucleotide compositions in the preparation of anti-aging and longevity-promoting drugs and / or functional foods Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to the application of 5'-monophosphate nucleotide compositions in the preparation of anti-aging and longevity-promoting drugs and / or functional foods. Background Technology
[0002] As people's living standards improve, China is about to enter an aging society, and delaying aging and achieving healthy longevity are goals for most people. Preventing and delaying aging has become a hot research topic. Human aging is a complex biological process involving multiple factors, including cellular, molecular, tissue, and organ levels. Mechanisms of aging include decreased intracellular antioxidant capacity and cellular metabolic disorders. Extending lifespan cannot be achieved through a single mechanism but requires the synergistic effect of multiple pathways, such as enhancing cellular antioxidant capacity, improving cellular metabolism, and activating cellular regeneration capacity, to achieve significant results.
[0003] Currently, the market offers a wide variety of products aimed at delaying aging or extending lifespan, including antioxidants, nutritional supplements, health products, and some medications. Antioxidants, such as vitamin C and vitamin E, slow aging by eliminating free radicals in the body; nutritional supplements, such as coenzyme Q10 and fish oil, maintain cellular function by providing the nutrients needed for cell metabolism; health products, such as ginseng and reishi mushrooms, enhance physical health by regulating the body's immune and endocrine systems; and some medications, such as metformin and rapamycin, delay aging through specific biological targets. While these products can improve certain aging-related indicators to some extent, their effects are limited.
[0004] However, existing products have many problems. First, most products have a single mechanism of action, targeting only a specific aging mechanism and failing to comprehensively improve the aging process. For example, antioxidants can only eliminate free radicals. Furthermore, the mechanisms of action of some existing products are not clearly defined, and systematic research is lacking, making their practical application effects difficult to predict. Therefore, developing a product with safe, effective, and non-toxic ingredients that can efficiently delay aging and extend lifespan has become a crucial issue that urgently needs to be addressed.
[0005] Nucleic acids are essential components of cells, composed of various nucleotides, and are divided into deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). They play a crucial role in the storage and transmission of genetic information and protein synthesis. As the basic building blocks of nucleic acids, nucleotides are widely distributed in various organs, tissues, and cells of organisms, participating in fundamental life activities such as heredity, development, and growth. Nucleotide compounds have important biological functions, participating in almost all biochemical processes in organisms, such as cellular energy metabolism, coenzyme synthesis, and cell signal transduction. Therefore, nucleotides and their derivatives have enormous potential in delaying aging. Summary of the Invention
[0006] Therefore, the object of the present invention is to provide the use of 5'-monophosphate nucleotide compositions in the preparation of anti-aging and longevity-promoting pharmaceuticals and / or functional foods.
[0007] The objective of this invention is achieved through the following means:
[0008] This invention provides the use of compositions of 5'-monophosphate nucleotides or their sodium salts in the preparation of anti-aging and longevity-promoting pharmaceuticals and / or functional foods.
[0009] Based on the above technical solution, the composition further comprises 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate and hypoxanthine nucleotide.
[0010] Based on the above technical solution, further, the mass ratios of each nucleotide in the composition converted to CMP, AMP, UMP, GMP, and IMP acid forms are as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0, or greater than 0 but not higher than 2.5%.
[0011] Based on the above technical solution, the mass ratios of the various nucleotides in the composition converted to CMP, AMP, UMP, GMP, and IMP acid forms are as follows: CMP: 15-45%, AMP: 15-25%, UMP: 15-30%, GMP: 15-35%, and IMP is 0, or greater than 0 but not higher than 2.5%.
[0012] Based on the above technical solution, the dosage form of the drug further includes powder, tablet, soft / hard capsule and oral liquid preparation.
[0013] Based on the above technical solution, the functional food further includes powders, tablets, soft / hard capsules, dairy products, baked goods, and liquid beverages.
[0014] Based on the above technical solution, the functional food and / or medicine further includes one or more nutritional supplements and food or medicine-acceptable excipients; the nutritional supplements include pyrrolizinone (PQQ), curcumin, resveratrol, and 6-gingerol.
[0015] Based on the above technical solution, the functional food and / or medicine further comprises 600-2400 parts of a composition in the form of 5'-monophosphate nucleotide or its sodium salt, 10-40 parts of PQQ, and 100-400 parts of curcumin; or 600-2400 parts of a composition in the form of 5'-monophosphate nucleotide or its sodium salt, 10-40 parts of PQQ, and 5-40 parts of resveratrol; or 600-2400 parts of a composition in the form of 5'-monophosphate nucleotide or its sodium salt, 10-40 parts of PQQ, and 5-40 parts of 6-gingerol.
[0016] Based on the above technical solution, the composition further improves the body's glucose and lipid metabolism by significantly reducing the insulin resistance index, thereby reducing the risk of diabetes.
[0017] Based on the above technical solution, the composition further improves the stability of the body's blood system by regulating the production or metabolism of blood cells such as platelets.
[0018] Based on the above technical solution, the composition further protects the stability of the nervous system and regulates the body's metabolic capacity by regulating the metabolism of essential minerals such as lithium (Li) and copper (Cu).
[0019] Based on the above technical solution, the composition further regulates the balance of intestinal flora by reducing the abundance of Klebsiella pneumoniae, thereby reducing the proportion of potentially pathogenic bacteria and maintaining the functional stability of normal flora.
[0020] Based on the above technical solution, further animal experiments showed that the composition extended the median survival time of mice by 9.21–12.6% compared with the control group, which is equivalent to 8.76–12.01 years in human life. Human trials showed that the composition reduced the median DNA methylation age by 3.08 years compared with the control group by regulating the DNA methylation clock.
[0021] The advantages of this invention over the prior art are as follows:
[0022] (1) This invention uses a specific ratio of 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate and hypoxanthine nucleotide, combined with nutritional supplements such as pyrroloquinoline quinone (PQQ), curcumin, resveratrol, and 6-gingerol, to synergistically eliminate free radicals in the body, inhibit the oxidative damage of free radicals to the body, and enhance the mitochondrial ATP production capacity and mitochondrial membrane potential, thereby enhancing mitochondrial activity and thus playing an anti-aging and life-extending role.
[0023] (2) The 5'-monophosphate nucleotide composition provided by the present invention can significantly reduce the insulin resistance index, significantly improve the glucose and lipid metabolism of the elderly, and reduce the risk of diabetes in the elderly.
[0024] (3) The 5'-monophosphate nucleotide composition provided by the present invention can enhance blood flow by reducing platelet hematocrit and increasing platelet average volume; at the same time, it can regulate the stability of the blood system by regulating the proportion of monocytes, erythrocytes, basophils and eosinophils in the blood.
[0025] (4) The 5'-monophosphate nucleotide composition provided by the present invention can protect the stability of the nervous system and regulate the body's metabolic capacity by regulating the metabolism of essential minerals such as lithium (Li) and copper (Cu).
[0026] (5) The 5'-monophosphate nucleotide composition provided by the present invention can regulate the balance of intestinal flora, reduce the proportion of potential pathogens, and maintain the functional stability of normal flora by reducing the abundance of Klebsiella pneumoniae in the intestine.
[0027] (6) The 5'-monophosphate nucleotide composition provided by the present invention exerts a synergistic effect by acting on different mechanisms of the body, maintaining the health status of the human body from the overall level, alleviating the damage caused by the external environment, and achieving the purpose of delaying aging and prolonging healthy life. Attached Figure Description
[0028] To more clearly illustrate the embodiments of the present invention, the accompanying drawings involved in the embodiments will be briefly described below.
[0029] Figure 1 shows the cumulative survival rate analysis of mice in each group in Example 10. In this figure, 1 represents the purified feed group (NTs-Free); 2 represents the normal control group; 3, 4, and 5 are the low, medium, and high dose intervention groups of NTs (NTs-L, NTs-M, and NTs-H), respectively; 6 represents the nicotinamide mononucleotide feeding group (NMN); and 7 represents the SAMR1 model control group.
[0030] Figure 2 is a PCA diagram comparing the overall structural changes of the gut microbiota in Example 11.
[0031] Figure 3 shows the effect of the nucleotide composition in Example 11 on the median DNA methylation age of elderly individuals. Detailed Implementation
[0032] The present invention will be described in detail below with reference to embodiments. However, the implementation of the present invention is not limited thereto. Obviously, the embodiments described below are only some embodiments of the present invention. For those skilled in the art, other similar embodiments can be obtained without creative effort and all fall within the protection scope of the present invention. Unless otherwise specified, the experimental methods in the following embodiments are conventional methods, performed according to the experimental methods or conditions described in the literature in the art or according to the kit instructions. The materials, reagents, instruments, etc. used in the following embodiments can all be obtained commercially.
[0033] Example 1
[0034] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, and disodium 5'-uridine monophosphate. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, and GMP, are as follows: CMP 43%, AMP 17%, UMP 22%, and GMP 18%.
[0035] The above four 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0036] Example 2
[0037] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, and disodium 5'-uridine monophosphate. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, and GMP, are as follows: CMP 18%, AMP 25%, UMP 24%, and GMP 33%.
[0038] The above four 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0039] Example 3
[0040] The 5'-monophosphate nucleotide composition used in this embodiment includes 5'-adenosine monophosphate, 5'-cytidine monophosphate, disodium 5'-guanylate, disodium 5'-uridine monophosphate, and hypoxanthine nucleotide. The effective percentage contents of each nucleotide, calculated as CMP, AMP, UMP, GMP, and IMP, are as follows: CMP 28%, AMP 24%, UMP 28%, GMP 19%, and IMP 1%.
[0041] The above five 5'-monophosphate nucleotides or their sodium salts were tested separately, and after passing the tests, they were passed through a 60-mesh sieve for later use. The required amount of each monophosphate nucleotide sample was weighed according to the above proportions, and the mixture was mixed for a time of not less than 40 minutes. The resulting mixed sample was stored at room temperature.
[0042] Example 4
[0043] Compared with Example 1, this embodiment also includes PQQ, curcumin, and a filler, as detailed below:
[0044] The composition used in this embodiment is formulated as follows: 5'-monophosphate nucleotide composition obtained in Example 1: 50%, PQQ: 0.7%, curcumin: 8%, with the remainder supplemented by microcrystalline cellulose, corn starch, magnesium stearate, etc.
[0045] After the raw materials pass the inspection, they are mixed for 30 minutes using an HZD-1000 mixer. The content of active ingredients in the finely mixed powder is then determined. The finely mixed powder is granulated and compressed into tablets, ensuring that each tablet weighs between 0.56g and 8%.
[0046] Example 5
[0047] Compared with Example 2, this embodiment also includes PQQ, resveratrol, and a filler, as detailed below:
[0048] The composition used in this embodiment is formulated as follows: 5'-monophosphate nucleotide composition prepared in Example 2: 55%, PQQ: 0.7%, resveratrol: 0.7%, with the remainder supplemented by microcrystalline cellulose, corn starch, magnesium stearate, etc.
[0049] After the raw materials pass the inspection, they are mixed for 30 minutes using an HZD-1000 mixer. The content of active ingredients in the finely mixed powder is then determined. The finely mixed powder is granulated and compressed into tablets, ensuring that each tablet weighs between 0.55g and 8%.
[0050] Example 6
[0051] Compared with Example 3, this embodiment also includes PQQ, 6-gingerol, and a filler. Details are as follows:
[0052] The composition used in this embodiment is formulated as follows: 70% of the 5'-monophosphate nucleotide composition obtained in Example 3, 1% of PQQ, 0.8% of 6-gingerol, with the remainder supplemented by microcrystalline cellulose, corn starch, magnesium stearate, etc.
[0053] After the raw materials pass the inspection, they are mixed for 30 minutes using an HZD-1000 mixer. The content of active ingredients in the finely mixed powder is then determined. The finely mixed powder is granulated and compressed into tablets, ensuring that each tablet weighs between 0.28g and 8%.
[0054] Example 7
[0055] This embodiment examines the antioxidant properties of the compositions prepared in Examples 1-6. The following description uses the 5'-monophosphate nucleotide composition prepared in Example 1 as an example.
[0056] The 5'-monophosphate nucleotide composition prepared in Example 1 was weighed and dissolved in a mixed solution of deionized water and ethanol (volume ratio 1:1) to obtain a mother liquor with a concentration of 1 mg / mL. The DPPH free radical scavenging rate and ABTS free radical scavenging rate were then determined.
[0057] 1. Determination of DPPH free radical scavenging rate:
[0058] The mother liquor was diluted 100, 50, 25, 10, and 1 times to prepare gradient dilutions with concentrations of 10 μg / mL, 20 μg / mL, 40 μg / mL, 100 μg / mL, and 500 μg / mL, respectively.
[0059] Take 150 μL of the sample at the above concentration and 150 μL of 60 mg / L DPPH solution (diluted with anhydrous ethanol) and place them in a 96-well plate, mix well, and store at 30°C in the dark. After 30 min, measure the absorbance at 519 nm using a microplate reader. The formula for DPPH free radical scavenging rate is as follows:
[0060] In the formula, Ablank represents the absorbance of 150 μL of deionized water ethanol solution and 150 μL of DPPH solution, and Asample represents the absorbance of 150 μL of sample and 150 μL of DPPH solution; IC0 50 The concentration of the sample when the DPPH free radical scavenging rate reaches 50%.
[0061] 2. Determination of ABTS free radical scavenging rate:
[0062] (1) The mother liquor was diluted by 100, 50, 25, 10 and 1 times to prepare gradient dilutions with concentrations of 10 μg / mL, 20 μg / mL, 40 μg / mL, 100 μg / mL and 500 μg / mL respectively.
[0063] (2) Mix 7 mmol / L ABTS solution and 140 mmol / L potassium persulfate solution in a ratio of 62.5:1, let stand overnight at room temperature in the dark to form ABTS stock solution, and dilute with deionized water to 5 mmol / L ABTS working solution before use.
[0064] (3) Take 0.15 mL of the above diluted sample and mix it with 2.85 mL of ABTS working solution. Let it stand at 30°C for 8 min. Use deionized water as a blank and measure the absorbance at 734 nm.
[0065] The formula for ABTS free radical scavenging rate is as follows:
[0066] In the formula, A blank is the absorbance of 0.15 mL of deionized water ethanol solution and 2.85 mL of ABTS working solution, and A sample is the absorbance of 0.15 mL of sample and 2.85 mL of ABTS working solution. IC 50 The concentration of the sample when the ABTS radical scavenging rate reaches 50%.
[0067] The antioxidant properties of the 5'-monophosphate nucleotide compositions in Examples 2-3 and the compositions in Examples 4-6 were tested using the same detection method described above. Control Test 1 used an amount of 5'-adenosine monophosphate equal to that of the 5'-monophosphate nucleotide composition in Example 1; Control Test 2 used an amount of 5'-cytidine monophosphate equal to that of the 5'-monophosphate nucleotide composition in Example 1; Control Test 3 used an amount of disodium 5'-guanylate equal to that of the 5'-monophosphate nucleotide composition in Example 1; and Control Test 4 used an amount of 5'-uridine equal to that of the 5'-monophosphate nucleotide composition in Example 1. Disodium phosphate was used as control test 4; hypoxanthine nucleotide in the same amount as the 5'-monophosphate nucleotide composition of Example 3 was used as control test 5; a composition containing only the same amount and ratio of PQQ and curcumin as the tablet of Example 4 was used as control test 6; a composition containing only the same amount and ratio of PQQ and resveratrol as the tablet of Example 5 was used as control test 7; and a composition containing only the same amount and ratio of PQQ and 6-gingerol as the tablet of Example 6 was used as control test 8. The test data are expressed as mean ± standard deviation, and the test results are shown in Table 1.
[0068] Table 1. Antioxidant properties of nucleotide-containing compositions
[0069] The above results indicate that, compared with the control groups 1-8, the 5'-monophosphate nucleotide compositions of Examples 1-3 and the compositions of Examples 4-6 all have higher antioxidant properties. The antioxidant properties of the 5'-monophosphate nucleotide compositions and the compositions of the 5'-monophosphate nucleotide compositions and the functional active ingredients are significantly enhanced, indicating that the compositions of Examples 1-6 can effectively scavenge free radicals in the body.
[0070] Example 8
[0071] This embodiment examines the effect of the compositions prepared in Examples 1-6 on improving mitochondrial function. The following description uses the 5'-monophosphate nucleotide composition prepared in Example 1 as an example.
[0072] Mitochondria are essential for life, participating in important physiological processes such as ATP production, apoptosis, and fatty acid β-oxidation. Mitochondrial ATP production capacity and mitochondrial membrane potential can reflect the functional state of mitochondria. Mitochondrial ATP production capacity was detected using a Seahorse XFe96 (Agilent) analyzer, and mitochondrial membrane potential was detected using JC-1 fluorescent dye.
[0073] Cell culture conditions: Mouse embryonic fibroblasts NIH / 3T3 (purchased from the Cell Bank of the Chinese Academy of Sciences) were cultured in DMEM high glucose medium containing 1% penicillin / streptomycin and 10% fetal bovine serum, and cultured in a 5% CO2 incubator at 37°C under saturated humidity; the senescent cell model was obtained by intervention with 200 μmol / L hydrogen peroxide for 4 h.
[0074] The specific experimental procedure for mitochondrial ATP production capacity is as follows: 2 × 10⁶ cells were seeded in each well of a 96-well cell culture plate (excluding the four background wells). 5NIH / 3T3 cells were cultured overnight. After cell adhesion, 200 μmol / L hydrogen peroxide was added for 4 h. The hydrogen peroxide-containing medium was then discarded, and complete medium containing 100 μg / mL of 5'-monophosphate nucleotides (DMEM high-glucose medium containing 1% penicillin / streptomycin and 10% fetal bovine serum) was added. The experimental group that was not treated with 200 μmol / L hydrogen peroxide and then added normal complete medium served as the positive control group, while the experimental group that was treated with 200 μmol / L hydrogen peroxide and then added normal complete medium served as the model control group. The cells were cultured for 24 h. One day in advance, hydrate the probe plate (XFe96FluxPak, Agilent, 102353-100) with hydration solution (XF Calibrant Solution, Agilent, 100840-000) and incubate it in a CO2-free incubator at 37℃ for more than 12 hours. On the day of the experiment, prepare the experimental culture medium by adding 1 ml of 2.5 mM glucose (Sigma, G7528), 2 mM glutamine (Sigma, G8540), and 1 mM sodium pyruvate (Sigma, S8636) to 100 ml of basal medium (Seahorse XF BaseMedium, Agilent, 102353-100). Adjust the pH of the solution to 7.4 ± 0.05 with 1 N NaOH. Change the medium in the cell culture plate, discarding 40 μL / well of the original medium, and dilute with 160 μL / well of the test culture medium. Then, aspirate 160 μL / well and repeat 2-3 times, with a final volume of 175 μL per well. Incubate at 37°C for 1 h. Add 25 μL / well of the drug to the probe plate. Add 2 μM oligomycin (Oligomycin, abcam, ab141829) to well A, 1 μM carbonyl-cyano-p-trifluoromethoxyphenylhydrazine (FCCP, Sigma, C2920) to well B, and 1 μM Antimycin A (abcam, ab141904) / Rotenone (Sigma, R8875) to well C. Calibrate the probe plate on the instrument. Analyze the cell culture plate on the instrument.
[0075] The specific experimental procedure for mitochondrial membrane potential is as follows: Seed 2 × 10⁶ cells per well of a 96-well cell culture plate (excluding the four background wells). 5NIH / 3T3 cells were cultured overnight. After cell adhesion, 200 μmol / L hydrogen peroxide was added for 4 h. The hydrogen peroxide-containing medium was then discarded, and complete medium containing 100 μg / mL of a 5'-monophosphate nucleotide combination (DMEM high-glucose medium containing 1% penicillin / streptomycin and 10% fetal bovine serum was added; the group without 200 μmol / L hydrogen peroxide treatment and then added to normal complete medium served as the positive control, while the group treated with 200 μmol / L hydrogen peroxide treatment followed by normal complete medium served as the model control) was cultured for 24 h. Cells were digested with trypsin, centrifuged to collect the cells, and incubated with mitochondrial membrane potential detection solution (JC-1) for 2 h. Cells were then washed with pre-cooled buffer, the supernatant was discarded, and the cells were collected into new EP tubes with fresh pre-cooled buffer added. 100 μL of cell culture was transferred to a 96-well plate, and the fluorescence intensity of the JC-1 polymer was detected. JC-1 is an ideal fluorescent probe widely used for detecting mitochondrial membrane potential. When the mitochondrial membrane potential is high, JC-1 aggregates in the mitochondrial matrix to form a polymer, which can produce red fluorescence. The higher the intensity of the red fluorescence, the higher the mitochondrial membrane potential and the higher the mitochondrial activity.
[0076] The effects of the 5'-monophosphate nucleotide compositions in Examples 2-3 and the compositions in Examples 4-6 on improving mitochondrial function were detected using the same detection method described above. Control experiment 1 used an amount of 5'-adenosine monophosphate equal to that of the 5'-monophosphate nucleotide composition of Example 1; control experiment 2 used an amount of 5'-cytidine monophosphate equal to that of the 5'-monophosphate nucleotide composition of Example 1; control experiment 3 used an amount of 5'-guanylate disodium equal to that of the 5'-monophosphate nucleotide composition of Example 1; control experiment 4 used an amount of 5'-uridine disodium equal to that of the 5'-monophosphate nucleotide composition of Example 1; control experiment 5 used an amount of hypoxanthine nucleotide equal to that of the 5'-monophosphate nucleotide composition of Example 3; control experiment 6 used a composition containing only the same amount and ratio of PQQ and curcumin as the tablets of Example 4; control experiment 7 used a composition containing only the same amount and ratio of PQQ and resveratrol as the tablets of Example 5; and control experiment 8 used a composition containing only the same amount and ratio of PQQ and 6-gingerol as the tablets of Example 6. The experimental data are expressed as mean ± standard deviation.
[0077] Table 2. Antioxidant properties of nucleotide-containing compositions
[0078] The results above show that, compared with the model control group, the mitochondrial ATP production capacity and mitochondrial membrane potential of mouse embryonic fibroblasts in control groups 1-8 were improved. The improvement effect of the composition test group of Examples 4-6 on the mitochondrial ATP production capacity and mitochondrial membrane potential of mouse embryonic fibroblasts was significantly better than that of control groups 1-8. The results indicate that the composition of the 5'-monophosphate nucleotide composition and the functional active ingredients of the present invention can synergistically improve the mitochondrial ATP production capacity and mitochondrial membrane potential of mouse embryonic fibroblasts, significantly improve mitochondrial function, increase mitochondrial activity, and keep the body's cells in a highly viable state.
[0079] Example 9
[0080] Metabolism produces a large number of free radicals, which damage cell function, lead to organ aging, and thus contribute to overall aging. Superoxide dismutase (SOD) can scavenge harmful superoxide anion free radicals. Glutathione peroxidase (GSH-Px) is an important peroxide-degrading enzyme widely present in the body. It can reduce toxic peroxides to non-toxic hydroxyl compounds, thereby protecting cell membrane structure and function from peroxide interference and damage. Therefore, SOD and GSH-Px activities can reflect the antioxidant capacity of tissues and are important indicators for evaluating aging. MDA, a lipid peroxidation product, is closely related to the production of free radicals and the degree of lipid peroxidation in tissue cells. It can reflect the oxidative stress damage state of tissues and is also an important indicator for evaluating aging. This example investigates the effects of the 5'-monophosphate nucleotide compositions in Examples 1-3 and the compositions in Examples 4-6 on delaying aging in rapidly aging-prone SAMP-8 mice (3 months old). The mice were housed in an SPF-grade animal facility at an ambient temperature of 22±2℃ and a relative humidity of 50%-60%, with a 12h / 12h (8:00-20:00) light pattern to simulate normal diurnal rhythms.Using the American Institute of Nutrition (AIN-93G) animal feed as the basal diet, and the above-mentioned composition as the intervention, the mice were fed 220 mg / kg BW by gavage daily for 60 days. The specific process is as follows: 75 rapidly aging mice (SAMP-8 mice, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.), weighing (20±5) g, were randomly divided into 15 groups of 5 mice each. The groups were: negative control group (fed only the basal diet), experimental group (composition groups of Examples 1-6), control group 1 (equivalent to 5'-adenosine monophosphate of the 5'-monophosphate nucleotide composition of Example 1), control group 2 (equivalent to 5'-cytidine monophosphate of the 5'-monophosphate nucleotide composition of Example 1), control group 3 (equivalent to 5'-guanylate disodium of the 5'-monophosphate nucleotide composition of Example 1), and control group 4 (equivalent to 5'-... The mice were divided into three groups: control group 5 (containing the same amount of hypoxanthine nucleotide as the 5'-monophosphate nucleotide composition of Example 3), control group 6 (containing only the same amount and ratio of PQQ and curcumin as the tablets of Example 4), control group 7 (containing only the same amount and ratio of PQQ and resveratrol as the tablets of Example 5) as control experiment 7, and control group 8 (containing only the same amount and ratio of PQQ and 6-gingerol as the tablets of Example 6). On the second day after the last feeding, blood was collected from the fundus of each group of mice. After the blood was allowed to stand at room temperature until it completely coagulated, the serum was separated by centrifugation for later use. The mice were then euthanized by dislocation, and the liver was quickly separated. After rinsing with sodium chloride solution, a 10% tissue homogenate was prepared. The homogenate was centrifuged, and the supernatant of the separated tissue homogenate was used for later use. The activities of SOD and GSH-Px in mouse serum and liver tissue were detected according to the instructions of the superoxide dismutase (SOD) assay kit and the glutathione peroxidase (GSH-Px) assay kit, respectively. The content of malondialdehyde (MDA) peroxide in mouse serum and liver tissue was determined by the thiobarbituric acid spectrophotometric method. The experimental data are expressed as mean ± standard deviation.
[0081] Table 3. Results of SOD, GSH-Px, and MDA levels in mice fed the compositions of Examples 1-6
[0082] It can be seen from the above results that compared with the negative control group, the SOD activity and GSH-Px activity in the serum and liver tissues of mice in control groups 1-8 are all increased, and the MDA content in the serum and liver tissues of mice is all decreased; the various indicators of the composition test groups of Examples 1-6 are significantly better than those of control groups 1-8. The results show that the 5'-monophosphate nucleotide composition of the present invention and the composition obtained by compounding the 5'-monophosphate nucleotide composition with functional active ingredients can synergistically enhance the body's ability to scavenge free radicals, reduce the degree of tissue cell damage, and delay the aging of the body.
[0083] Example 10
[0084] This example investigates the effect of lifelong intervention with the 5'-monophosphate nucleotide composition prepared in Example 1 on the survival time of SAMP8 mice.
[0085] 1. Sample: The 5'-monophosphate nucleotide composition obtained in Example 1 above.
[0086] 2. Experimental animals: 350 healthy 3-month-old Specific Pathogen Free (SPF) grade male senescence-accelerated mouse prone 8 (SAMP8) and senescence-accelerated mouse resistant 1 (SAMR1) model control mice were selected, purchased from the Laboratory Animal Center of Peking University Health Science Center (Laboratory Animal Production License No.: SCXK (Beijing) 2016-0010; Laboratory Animal Use License No.: SYXK (Beijing) 2016-0041). During the experiment, the animals were raised in single cages, the temperature of the animal room was controlled at 22±2°C, the relative humidity was maintained at 50% to 60%, and the light-dark cycle of day: night was 12h: 12h.
[0087] 3. Experimental grouping and dosage: After one week of adaptive feeding, SAMP8 mice were randomly divided into 6 groups according to body weight (n=50): nucleotide-free group (purified feed, NTs-Free), normal control group (basic feed, Normal control), low, medium and high dose intervention groups of the composition described in Example 1 (0.3g / kg, 0.6g / kg, 1.2g / kg, corresponding to NTs-L, NTs-M, NTs-H respectively) and nicotinamide mononucleotide feeding group (NMN, 0.3g / kg), and a SAMR1 model control group (basic feed, n=50) was set up. The nucleotide mixture and nicotinamide mononucleotide were incorporated into the basic feed at different doses for intervention. Starting from the age of 3 months of the mice, each group was given the corresponding feed for lifelong feeding intervention, and the animals had free access to drinking water and food during the experiment; the intervention and grouping of experimental animals are shown in Table 4.
[0088] Table 4. Grouping and intervention of experimental animals
[0089] 4. Experimental method:
[0090] During the experiment, mice were housed individually in cages, and no other factors interfered except for routine procedures performed by researchers (cleaning the cages and general observation). The times when mice were found to have died naturally or were euthanized (i.e., observed to be in extremely poor condition and judged to have a very low probability of survival within 48 hours) were recorded in detail for lifespan analysis. Euthanasia was performed for humane reasons, and euthanized mice were considered to have a complete lifespan and could be used for lifespan analysis. The criteria for euthanasia were based solely on the animal's condition, referring to AAALAC guidelines, relevant literature review, and the team's previous experience in lifelong feeding experiments. Key indicators included: severe lethargy, rapid weight loss (>20% over two weeks), severe abdominal distension and physical condition score accompanied by signs of pain (judged by facial expressions, appearance, behavioral abnormalities, and other common mouse pain symptoms), unresponsiveness to stimuli or external behaviors, severe ulcers or hemorrhagic tumors, and severe hypothermia accompanied by abnormal respiratory rate. After the experiment, the survival time of mice in each group was summarized and analyzed using SPSS 24.0 software. Kaplan-Meier survival analysis was performed, and Log Rank (Mantel-Cox) was used for intergroup comparisons. P < 0.05 was used as the statistical threshold.
[0091] 5. Experimental Results
[0092] 5.1. Effect of lifelong intervention with the composition described in Example 1 on the survival of SAMP8 mice
[0093] As shown in Table 5, intervention began in all groups of mice at 3 months of age. Mortality began gradually after 6 months of age, with the NMN group experiencing the first two deaths at 7 months, followed by deaths in all other groups at 8 months. After 12 months of age, the mortality rate accelerated significantly in all groups, with the NTs-L and NTs-M groups showing lower mortality rates than the other groups. At 18 months of age, the NTs-L and NTs-M groups had the highest number of surviving mice, with survival rates of 26% and 20%, respectively. At 20 months of age, no mice survived in the NTs-Free, Normal, and NTs-H groups. By 23 months of age, only the NTs-L and NTs-M groups had surviving mice (2 mice each). The NTs-L group had the longest survival time at 24.93 months, close to 25 months, followed by the NTs-M group at 23.83 months.
[0094] Table 5. Survival status of mice in each group from 3 to 25 months of age.
[0095] 5.2. Effect of lifelong intervention with the composition described in Example 1 on the survival time of SAMP8 mice
[0096] As shown in Table 6, the mean survival time (14.98 m) and median survival time (14.30 m) of the NTs-L group were both higher than those of the other groups, followed by the NTs-M group (mean survival time 14.65 m, median survival time 13.87 m). Analyzing the median survival time, the median survival time of the NTs-L group (14.30 m) was extended by 12.6%, 5.93%, and 5.38% compared to the NTs-Free (12.70 m), Normal control (13.50 m), and NMN group (13.57 m), respectively. The median survival time of the NTs-M group (13.87 m) was extended by 9.21%, 2.74%, and 2.21% compared to the NTs-Free (12.70 m), Normal control (13.50 m), and NMN group (13.57 m), respectively.
[0097] Table 6. Effects of lifelong intervention with NTs on survival time of mice in each group.
[0098] As shown in Figure 1, the cumulative survival rate of mice revealed that the NMN group was the first to die (corresponding to age 6.37 months), and its cumulative survival rate was lower than that of other groups before 10 months of age. At a cumulative survival rate of 50%, the NMN group corresponded to an age of 13.57 months, higher than the NTs-Free (12.70 months), Normal control (13.50 months), and NTs-H (12.77 months) groups, but lower than the NTs-L (14.30 months) and NTs-M (13.87 months) groups. At 14 months of age, the cumulative survival rates of the NTs-L and NTs-M groups were 52% and 46%, respectively, higher than other groups. Furthermore, in subsequent months, the cumulative survival rates of the NTs-L and NTs-M groups remained higher than other groups, with the NTs-L group having the longest survival time (24.93 months), followed by the NTs-M group (23.83 months). Intergroup comparisons using Log Rank (Mantel-Cox) revealed that, compared to the NTs-Free group, the NTs-L group showed: χ² 2 =5.26, P=0.022; Ratio of NTs-M to NTs-Free groups: χ² 2 =5.40, P=0.020, all of which were statistically significant (P<0.05). The test results for NTs-L compared with the Normal control and MNM groups were respectively (χ²) 2 =5.40, P=0.071), (χ²) 2 =3.07, P=0.08). SAMR1 was the model control group, except for the NTs-L group (χ² = 3.07, P = 0.08). 2 =3.07, P=0.536), and NTs-M group (χ²) 2Except for the group with a cumulative survival rate of 2.62 (P=0.105) which showed no statistically significant difference (P>0.05), the cumulative survival rate of the group with a cumulative survival rate of 2.62 (P=0.105) was significantly higher than that of the other groups (P<0.01).
[0099] The above results indicate that long-term intervention with the composition described in Example 1 can effectively reduce the mortality rate, prolong the survival time, and increase the lifespan of mice. The NTs-L group had the longest average lifespan (14.98m), median survival time (14.3m), and longest survival time (24.93m). Compared to the NTs-Free, Normal control, and NMN groups in this study, the median survival time was extended by 12.6%, 5.93%, and 5.38%, respectively.
[0100] In summary, the experimental results show that long-term intervention with the composition described in Example 1 can effectively reduce the mortality rate of mice, prolong their survival time, and improve their lifespan, thus having a highly positive promoting effect on improving quality of life. Its lifelong intervention in SAMP8 mice extended the median survival time by 9.21–12.6% compared to the control group, which is equivalent to an estimated human lifespan of 8.76–12.01 years.
[0101] Example 11
[0102] This embodiment employs a randomized, double-blind experimental design to evaluate the application effect of the 5'-monophosphate nucleotide composition prepared in Example 1 in the elderly population.
[0103] 1. Test Methods
[0104] 1.1. Experimental Design and Participants
[0105] This trial is an exploratory, 19-week, single-center, double-blind, randomized, placebo-controlled study that recruits community residents through advertising for a comprehensive health assessment, including clinical health check-ups, questionnaires, physical function assessments, and anthropometry. Eligibility was determined according to the following criteria: Inclusion criteria: (1) Age between 60 and 70 years; (2) No serious physical or mental illness; (3) No prior use of nucleotide-related supplements or health foods; (4) Ability to follow the study protocol and provide informed consent. Exclusion criteria: (1) Diagnosed diseases such as autoimmune diseases, serious cardiovascular and cerebrovascular diseases, complications of major organs such as the liver and kidneys, or other serious diseases such as malignant tumors, pancreatic diseases, and mental illnesses; (2) Abnormal screening laboratory test values or other laboratory test results, excluding the researcher's judgment; (3) Severe visual or hearing impairments that affect communication; (4) Participation in other clinical trials within the past 6 months; (5) Use of foods or drugs related to the function being tested. All participants provided informed written consent in accordance with the Declaration of Helsinki prior to their recruitment into the study.
[0106] 1.2. Sample size and randomization
[0107] The sample size for this trial was determined according to the "Technical Specifications for Inspection and Evaluation of Health Foods" issued by the National Health Commission of China, which recommends at least 50 participants per group in human intervention trials. Participants were randomly assigned to the intervention group and the control group in a 1:1 ratio. To estimate a 20% loss to follow-up rate, a total of 120 participants were included in the study.
[0108] Participants are randomly assigned to groups using computer-generated random numbers. The protocol is known only to the trial designers, who are not involved in data collection or analysis. The randomization code is sealed and is only unblinded in the event of a serious adverse event.
[0109] 1.3. Intervention and blinding
[0110] This trial included a nucleotide intervention group and a placebo control group. The intervention was administered in capsule form to ensure consistency in appearance, taste, and formulation between the placebo (pure starch excipient) and the intervention (the 5'-monophosphate nucleotide composition described in Example 1 plus starch excipient), thus avoiding any suspicion among participants. The placebo capsules were designed similarly to the intervention capsules. Each capsule in the nucleotide intervention group contained 0.1 g of starch excipient and 0.3 g of the 5'-monophosphate nucleotide composition described in Example 1, while each placebo capsule contained 0.4 g of starch excipient. Participants were instructed to take four capsules daily while maintaining a regular lifestyle and diet. The double-blind design ensured that participants and researchers, including investigators, clinicians, data collectors, and follow-up coordinators, were unaware of group assignments. The capsules were packaged in opaque bottles labeled only with the participant identifier. The blinding procedure was explained in detail to participants during the informed consent process.
[0111] 1.4. Participation in the Experiment
[0112] After screening, 122 participants were selected as eligible to participate. The intervention lasted for 19 weeks. During the follow-up period, except for one participant in the nucleotide group who withdrew after one week of intervention due to a traffic accident, the remaining 121 participants completed the trial. A total of 121 participants who completed the intervention were ultimately included in the statistical analysis. There were no significant differences between the two groups in any baseline characteristics. The mean age of the participants was 65.65 years (standard deviation 2.59), of whom 82 (67.21%) were female.
[0113] 1.5. Data Collection
[0114] In the trial, data collection at the baseline (T0), mid-term (T1), and final (T2) periods was conducted by hospitals that performed clinical examinations and collected biological samples (blood, urine, and stool).
[0115] DNA methylation data were acquired through whole-genome bisulfite sequencing (WGBS), with the sequencing work outsourced to BGI Genomics (Shenzhen, China). SOAPnuke and Bismark software were used for data filtering, alignment, and methylation site localization.
[0116] Insulin resistance was calculated using the Homeostasis Model Assessment-IR (HOMA-IR), a widely used surrogate indicator. The formula is: (fasting blood glucose [mmol / L] * fasting insulin [mIU / L]) / 22.5.
[0117] 1.6. Statistical Analysis
[0118] The data analysis in this study followed the intention-to-treat (ITT) principle, and no imputation was performed on missing data in the baseline data. The Shapiro-Wilk test was used to assess data normality, and the Levene test was used to assess homogeneity of variance. Based on the distribution characteristics of the variables, the independent samples t-test (for normally distributed data) or the Mann-Whitney U test (for non-normally distributed data) was used to compare pre-intervention, post-intervention, and changes between groups. The effect size was calculated using Cohen's d-value, derived from the difference between the means of the two groups, where d = 0.2 was a small effect size, d = 0.5 was a moderate effect size, and d = 0.8 was a large effect size.
[0119] We used generalized estimating equations (GEE) to analyze all outcome measures, specifying an exchangeable work-related structure. Data from all baselines and endpoints were used in the trial. Independent variables in Model 1 included group, time, group-time interaction terms, baseline dependent variable (a continuous variable), age, and sex. We also constructed Model 2, further adjusting for dietary nucleotide intake. Similarly, Model 3 further adjusted for dietary purine intake. The intervention effect was determined by the coefficients of the interaction terms in the models and their 95% confidence intervals (CIs).
[0120] 2. Test Results
[0121] 2.1 Effects of nucleotide compositions on mineral content in the elderly
[0122] This study used a t-test to analyze the effects of exogenous nucleotide intervention on the levels of multiple minerals in elderly individuals. The results are shown in Table 7. The results indicated a significant difference between the intervention group and the control group at the intervention endpoint (T2).
[0123] Table 7. Effects of nucleotide compositions on the body's mineral content
[0124] Independent samples t-test results showed that, regarding changes in lithium (Li) concentration, at the intervention endpoint (T2), the lithium concentration in the nucleotide intervention group (1.57±0.37 ng / ml) was significantly lower than that in the control group (1.74±0.52 ng / ml), P=0.033, Cohen's d=-0.39. Furthermore, the copper (Cu) concentration at the intervention endpoint (1012.67±114.74 ng / ml) was significantly higher than that in the control group (969.44±109.94 ng / ml), P=0.039, Cohen's d=0.38.
[0125] The results of this study indicate that exogenous nucleotide intervention significantly affected the levels of some minerals, especially at the intervention endpoint (T2), where the difference between the intervention group and the control group was more pronounced, suggesting that nucleotides may play a role in mineral metabolism. Regarding lithium (Li), the lithium concentration in the nucleotide intervention group was significantly lower than that in the control group at the intervention endpoint (T2). Lithium, as a trace element related to neuroregulation, plays an important role in mood stability, neuronal signaling, and neuroprotection. Its decreased level may suggest that nucleotide intervention affected lithium absorption, distribution, or excretion to some extent. Considering that lithium is mainly excreted through the kidneys, nucleotides may affect its renal tubular reabsorption or excretion mechanism. Regarding copper (Cu), the copper concentration in the nucleotide intervention group was significantly higher than that in the control group at the intervention endpoint (T2). Copper is an essential trace element in the body, playing an important role in iron metabolism, antioxidant defense, immune function, and neurotransmission. Its increased concentration may indicate that nucleotide intervention promoted copper absorption or affected the regulation of copper in the body. Previous studies have shown that nucleotides may indirectly promote copper metabolism and utilization by affecting the expression of metal transport proteins or regulating oxidative stress levels.
[0126] 2.2 Effects of nucleotide compositions on glucose and lipid metabolism in the elderly
[0127] This part of the experiment aims to comprehensively evaluate the effects of exogenous nucleotides on glucose and lipid metabolism in the elderly, mainly through analysis of indicators such as fasting blood glucose (FBG) and insulin resistance index (HOMA-IR).
[0128] Table 8. Results of glucose and lipid metabolism indicators in the subjects
[0129] The results show that from baseline to the midpoint of the intervention, fasting blood glucose decreased in the NTs group and increased in the C group (NTs: -0.13±0.66, C: 0.20±0.84), with a statistically significant difference (P=0.02), and the effect size between groups was moderate (d=-0.43). From baseline to the intervention endpoint, insulin resistance index decreased in the NTs group and increased in the C group (NTs: -0.27±1.45, C: 0.19±0.74), with a statistically significant difference (P=0.03), and the effect size between groups was moderate (d=-0.41).
[0130] These results indicate that exogenous nucleotide supplementation can significantly improve glucose and lipid metabolism in older adults, particularly in terms of insulin resistance index. The supplementation of exogenous nucleotides was associated with a significant reduction in insulin resistance index, a change that may help maintain glycemic homeostasis and reduce the risk of diabetes in older adults.
[0131] 2.3 Effects of nucleotide compositions on blood routine tests in the elderly
[0132] This part of the experiment aims to comprehensively evaluate the effects of exogenous nucleotides on blood routine tests in elderly individuals, focusing on analyzing multiple hematological indicators and exploring their potential effects on the immune system and overall health of the elderly. The experiment includes routine hematological indicators such as white blood cell count, platelet count, and hemoglobin, as well as immune cell-related indicators such as the percentage and absolute values of lymphocytes, neutrophils, monocytes, eosinophils, and basophils.
[0133] Table 9. Results of glucose and lipid metabolism indicators in the subjects
[0134] The results above indicate that at baseline, there were no significant differences in any blood routine indicators between the two groups of elderly individuals (P>0.05), suggesting that the baseline blood routine conditions of the two groups were comparable. Analysis of the differences between groups in the changes before and after the intervention (T2-T0) revealed that the platelet count changes were opposite in direction: the platelet count decreased in the NTs group and increased in the C group (NTs: -11.60±30.76, C: 6.87±51.56), and the difference was statistically significant (P=0.019), with a moderate effect size (d=0.43). Plateletcrit increased in both groups, but the change was smaller in the NTs group than in the C group (NTs: 0.01±0.03, C: 0.02±0.03), and the difference was statistically significant (P=0.037), with a moderate effect size (d=0.39). The percentage of basophils increased in both groups. The percentage change in basophils in the NTs group was smaller than that in the C group (NTs: -0.01±0.12, C: -0.05±0.11), with a statistically significant difference (P=0.069) and a small effect size (d=0.34). The absolute number of basophils decreased in both groups, but the change in the absolute number of basophils in the NTs group was greater than that in the C group (NTs: 0.00±0.01, C: -0.00±0.01), with a statistically significant difference (P=0.037) and a small effect size (d=0.39). Overall, nucleotide intervention caused some changes in blood routine indicators, especially in platelet-related indicators. Specifically, platelet count and plateletcrit decreased in the NTs group, while mean platelet volume increased. A decrease in platelet count may reflect the potential impact of exogenous nucleotides on platelet production or function, suggesting that they may affect platelet quantity by regulating cell production or metabolic pathways in the blood. Meanwhile, an increase in plateletcrit indicates an increase in platelet volume, which may mean that individual platelets are becoming larger or more active. Increased platelet volume is usually closely related to platelet functional activity and may have some impact on blood coagulation. In summary, changes in platelet-related parameters in the NT group may indicate that nucleotides have a regulatory role in the blood system, particularly in physiological processes such as immune responses and blood coagulation, potentially playing a biological role.
[0135] 2.4 Effects of nucleotide compositions on metagenomics in older adults
[0136] This study employed high-throughput sequencing technology to analyze the metagenomics of an elderly population and explore the impact of exogenous nucleotides on the gut microbiota. First, gut samples were collected from participants, and total DNA was extracted using standardized DNA extraction methods. Subsequently, metagenomic sequencing was performed on the extracted DNA samples using the DNBSEQ platform to obtain raw sequencing data. All raw data underwent rigorous quality control, with host genome sequences removed using software tools to ensure the accuracy and reliability of the final data. Genome assembly was performed on the processed sequence data. MEGAHIT was used for k-mer assembly to generate contigs, followed by gene prediction using MetaGeneMark to obtain relevant gene information. Based on this, species classification was performed using the Kraken2 tool, sequence alignment was performed, and the abundance of each microorganism in the samples was calculated.
[0137] To comprehensively understand the impact of exogenous nucleotides on the microbial community, we performed diversity analysis on the measured gene abundance, species abundance, and functional abundance tables. By calculating α-diversity (species richness and evenness) and β-diversity (differences in community structure), we assessed the differences in microbial communities between different groups. PCA dimensionality reduction was used to further visualize the differences between samples, helping to reveal the potential impact of nucleotide intervention on microbial community structure. GEE was used to assess the impact of exogenous nucleotide intervention on α-diversity and differentially expressed microbiota; a p-value < 0.05 was considered statistically significant in the GEE analysis.
[0138] Table 10. Effects of nucleotide compositions on gut α-microbiota diversity in older adults
[0139] *T0 represents the baseline time point, and T2 represents the intervention endpoint time point (19 weeks).
[0140] *The p-value is based on a generalized estimation equation. The model considers the interaction between group and time, as well as covariates. The assessment time points include baseline and intervention endpoint. Adjusted covariates include baseline value, age, and sex.
[0141] *Only α diversity indicators with p-values < 0.05 are listed in the table.
[0142] Table 11. Significantly Differential Species in the Effects of Nucleotide Compositions on Gut Microbiota in the Elderly
[0143] *T0 represents the baseline time point, and T2 represents the intervention endpoint time point (19 weeks).
[0144] *The p-value is based on a generalized estimation equation. The model considers the interaction between group and time, as well as covariates. The assessment time points include baseline and intervention endpoint. Adjusted covariates include baseline value, age, and sex.
[0145] *Only bacterial species with a p-value < 0.05 are listed in the table.
[0146] Regarding alpha diversity, at the family level, the Shannon and Simpson indices showed significant differences in changes between groups before and after intervention (T2 vs. T0). Specifically, the mean difference in the Shannon index was -0.25 (P = 0.026), and the mean difference in the Simpson index was -0.059 (P = 0.019). Other levels of alpha diversity did not show statistical significance. Nucleotide intervention reduced both the Shannon and Simpson indices, indicating changes in the richness and evenness of the gut microbiota. The decrease in the Shannon index may indicate a reduction in the abundance of certain bacterial groups, leading to some adjustment in the microbiota structure, while the change in the Simpson index may suggest a change in the proportion of dominant species within the microbiota. This change may be related to nucleotide regulation of host metabolism, the immune system, and competition among gut microbiota. Microbiota diversity is crucial for maintaining gut homeostasis; moderate changes in diversity may reflect optimized microbiota function rather than simple microbiota imbalance, suggesting that nucleotide intervention may promote adaptive structural adjustments in the microbiota, thereby optimizing its ecological stability.
[0147] Beta diversity analysis compared changes in the overall gut microbiota structure using PCA plots (Figure 2), showcasing the results of beta diversity analysis of metagenomic data. Principal component analysis (PCA) visualized the distribution of different sample populations in two-dimensional space, with each color representing a different sample group (red, green, blue, and yellow), and each point representing the position of a sample in the principal component space. The ellipses shown in the figure represent the distribution range of each group, reflecting the variability between samples and the distance between populations. This PCA plot allows for a direct observation of the similarities and differences between different sample groups. The results showed no significant difference in microbiota composition between the nucleotide intervention group and the control group, indicating that there were no significant changes in the overall microbiota structure between the groups.
[0148] Differential species analysis revealed statistically significant differences in some species before and after intervention at both the genus and species levels. At the genus level, the mean difference between groups of *Klebsiella* was -0.035 (P = 0.022); at the species level, the mean difference between groups of *Klebsiella pneumoniae* was -0.028 (P = 0.030). This indicates that exogenous nucleotide intervention may affect the abundance of specific gut microbiota species. Furthermore, nucleotide intervention led to a significant decrease in the abundance of *Klebsiella pneumoniae*, a phenomenon with important biological significance. *Klebsiella pneumoniae* is an opportunistic pathogen that can become a potential pathogen in cases of gut microbiota imbalance, host immunodeficiency, or antibiotic use, and is associated with antibiotic resistance, chronic inflammation, and metabolic disorders. Its decreased abundance suggests that nucleotides may inhibit the colonization and growth of this bacterium by regulating intestinal barrier function, enhancing host immunity, or affecting metabolic competition among microbiota. It is noteworthy that although the abundance of some bacteria changed, nucleotides did not have a significant impact on the overall microbial community structure, suggesting that their role may be to locally regulate the microbial community balance rather than to completely reshape the microbial community ecology. This may help reduce the proportion of potentially pathogenic bacteria while maintaining the functional stability of normal microbial communities.
[0149] In summary, this study found that exogenous nucleotide intervention primarily affected gut microbiota by reducing α-diversity and decreasing the abundance of specific bacterial species (such as Klebsiella pneumoniae), but did not significantly impact the overall microbiota structure. This suggests that nucleotides may exert a potential health-promoting effect by moderately regulating gut microbiota ecology and optimizing microbiota composition without disrupting microbiota homeostasis.
[0150] 2.5 Effect of nucleotide composition on median DNA methylation age in older adults
[0151] This study employed whole-genome methylation sequencing (WGBS) to investigate the methylation status of the genome, and used BGI's proprietary SOAPnuke software (version v1.5.6) for data quality control. Comparison of data from the nucleotide intervention group and the placebo control group showed that the nucleotide group exhibited a mean difference of β = -3.08 years (95% confidence interval: -5.07 to -1.10, P = 0.0023 for Model 1), indicating a significant reduction in biomarkers of aging. This significant reduction was consistent across all models (P < 0.01 for Model 2 and Model 3), as shown in Figure 3.
[0152] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; modifications or equivalent substitutions may be made to the technical solutions described in the foregoing embodiments, and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. Use of a composition of 5'-monophosphate nucleotides or sodium salt forms thereof for the preparation of a drug and / or a functional food against senescence, characterized in that, The composition consists of 5'-monophosphate adenosine, 5'-monophosphate cytidine, 5'-guanylic acid disodium, 5'-uridine acid disodium and hypoxanthine nucleotide; the mass ratio of each nucleotide in the composition converted into CMP, AMP, UMP, GMP, IMP acid type is respectively: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, IMP is 0 or greater than 0 and not higher than 2.5%.
2. Use according to claim 1, characterized in that, The mass ratio of each nucleotide in the composition converted into CMP, AMP, UMP, G MP, IMP acid type is respectively: CMP: 15-45%, AMP: 15-25%, UMP: 15-30%, GMP: 15-35%, IMP is 0 or greater than 0 and not higher than 2.5%.
3. Use according to claim 1, characterized in that, Dosage forms of the drug include powders, tablets, soft / hard capsules and oral liquid preparations; The functional food includes powders, tablets, soft / hard capsules, dairy products, baked products and liquid beverages.
4. Use according to claim 1, characterized in that, The functional food and / or drug also contains one or more than two nutritional supplements and food or drug acceptable excipients; the nutritional supplements include pyrroloquinoline quinone (PQQ), curcumin, resveratrol, 6-gingerol.
5. Use according to claim 4, characterized in that, The functional food and / or drug contains 5'-monophosphate nucleotide or its sodium salt form composition 600-2400 parts, PQQ 10-40 parts, curcumin 100-400 parts; or 5'-monophosphate nucleotide or its sodium salt form composition 600-2400parts, PQQ 10-40 parts, resveratrol 5-40 parts; or 5'-monophosphate nucleotide or its sodium salt form composition 600 -2400 parts, PQQ 10-40 parts, 6-gingerol 5-40 parts.
6. Use according to claim 1, characterized in that, The composition significantly reduces the insulin resistance index, improves the body's sugar and lipid metabolism capacity, and reduces the risk of diabetes in the body.
7. The use according to claim 1, characterized in that, The composition significantly improves the stability of the body's blood system by regulating the production or metabolic pathways of blood cells such as platelets.
8. The use according to claim 1, characterized in that, The composition protects the stability of the nervous system by regulating the metabolism of lithium (Li) and copper (Cu) essential minerals, and regulates the metabolic capacity of the body.
9. The use according to claim 1, characterized in that, The composition reduces the abundance of Klebsiella pneumoniae in the intestinal tract, regulates the balance of intestinal flora, reduces the proportion of potential pathogenic bacteria, and maintains the functional stability of normal flora.
10. The use according to claim 1, characterized in that, According to animal experiment research, the composition prolongs the median survival time of mice by 9.21-12.6%, which is equivalent to 8.76-12.01 years of human life; according to human experiment research, the composition reduces the median age of DNA methylation by 3.08 years compared with the control group by regulating the DNA methylation clock.
